News Archives Year: 2018

Retrotope Announces First Dosing of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD)

Immusoft Receives Rare Pediatric Disease Designation For Treatment Of MPS I

VelosBio raises $58M in Series A round for antibody-drug conjugate development

Oncternal Announces First Patient Dosed in Phase 1b Clinical Trial of Cirmtuzumab in Combination with Paclitaxel in Patients with Breast Cancer

Nabriva Therapeutics Strengthens Antibiotics Leadership Position with Acquisition of Zavante Therapeutics

Jason Fontenot, Ph.D., Joins Immusoft As Chief Scientific Officer

Retrotope Announces Publication of Preclinical Research Showing Cognitive Improvements in a Huntington’s Disease Model Using Deuterated Polyunsaturated Fatty Acid (D-PUFA) Drug Candidate

Oncternal Announces Publication of Data from Phase 1 Trial of Cirmtuzumab in CLL in Cell Stem Cell

SelectION Appoints Antonius Schuh as New CEO

Immusoft Granted Orphan Drug Designation For Treatment Of Rare Childhood Disease